Carregant...
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR) have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymphoma (B-...
Guardat en:
| Publicat a: | Blood Adv |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6482360/ https://ncbi.nlm.nih.gov/pubmed/30979721 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018029678 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|